Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-10-17
2010-06-08
Kolker, Daniel E. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387300, C435S007200
Reexamination Certificate
active
07731962
ABSTRACT:
The present invention relates to antibodies that differentially recognize multi-dimensional conformations of Aβ-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid β 1-42.
REFERENCES:
patent: 6218506 (2001-04-01), Krafft et al.
patent: 6492123 (2002-12-01), Holliger et al.
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 6761888 (2004-07-01), Schenk
patent: 6787637 (2004-09-01), Schenk
patent: 6797492 (2004-09-01), Daugherty et al.
patent: 6913745 (2005-07-01), Schenk
patent: 2003/0068316 (2003-04-01), Klein et al.
patent: 2006/0057701 (2006-03-01), Rosenthal et al.
patent: WO 97/11971 (1997-04-01), None
patent: WO 03/104437 (2003-12-01), None
patent: WO 2005/025516 (2005-03-01), None
Paul W. E. Fundamental Immunology, 3rd edition, 1993, pp. 292-295.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Armour et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities”, Eur. J. Immuno. 1999 29:2613.
Birmingham, K. and Frantz, S., “Set back to Alzheimer vaccine studies”, Nat. Med. 2002 8:199-200.
Bitan et al., “Neurotoxic protein oligomers—what you see is not always what you get”, Amyloid 2005 12(2):88-95.
Canfield and Morrison, “The Binding Affinity of Human IgG for its High Affinity Fc Receptor Is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region”, J. Exp. Med. 1991 173:1483-1491.
Chang et al., “Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening”, J. Molecular Neuroscience 2003 20:305-313.
Dodart et al., “Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model”, Nat. Neurosci. 2002 5:452-457.
Gong et al., “Alzheimer's disease-affected brain:Presence of oligomeric Aβligands (ADDLs) suggests a molecular basis for reversible memory loss”, Proc. Natl. Acad. Sci. USA 2003 100:10417-10422.
Hardy et al., “The Amyloid Hypothesis of Alzheimer's Disease:Progress and Problems on the Road to Therapeutics”, Science 2002 297:353-356.
Hock et al., “Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease”, Neuron 2003 38:547-554.
Hougs et al., “The first constant-domain (CH1) exon of humanIGHG2is polymorphic and in strong linkage disequilibrium with the CHW exon polymorphism encoding the G2m(n+) allotype in Caucasians”, Immunogenetics 2001 52:242-248.
Ida et al., “Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and blood by a Newly Developed Sensitive Western Blot Assay”, J. Biol. Chem. 1996 271(37):22903-22914.
Kayed et al., “Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis”, Science 2003 300:486-489.
Klein, William L., “Aβ toxicity in Alzheimer's disease:globular oligomers (ADDLs) as new vaccine and drug targets”, Neurochemistry International 2002 41:345-352.
Kotilnek et al., “Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease”, J. Neurosci 2002 22:6331-6335.
Lambert et al., “Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies”, J. Neurochemistry 2001 79:595-605.
Lambert et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42are potent central nervous system neurotoxins”, Proc. Natl. Acad. Sci. USA 1998 95:6448-6453.
Lathe, R., “Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data—Theoretical and Practical Considerations”, J. Mol. Biol. 1985 183:1-12.
Lu et al., “A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor”, Nat. Med. 2000 6:397-404.
Medgyesi et al., “Functional mapping of the FcγRll binding site on human IgG1 by synthetic peptides”, Eur. J. Immunol. 2004 34:1127-1135.
Padlan, Eduardo A., “Anatomy of the Antibody Molecule”, Molecular Immunology 1994 31(3):169-217.
Tao et al., “The Differential Ability of Human IgG1 and IgG4 to Activate Complement Is Determined by the COOH-terminal Sequence of the CH2 Domain”, J. Exp. Med. 1991 173:1025-1028.
Xu et al., “Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement”, J. Biol. Chem 1994 269:3469-3474.
Zuckier et al., “The Use of Severe Combined Immunodeficiency Mice to Study the Metabolism of Human Immunoglobulin G”, Cancer Suppl. 1994 73:794-799.
Terry et al., “Physical Basis of Cognitive Alterations in Alzheimer's Disease:Synapse Loss Is the Major Correlate of Cognitive Impairment”, Ann Neurol 1991 30:572-580.
Selkoe, Dennis J., “Alzheimer's Disease Is a Synaptic Failure”, Science 2002 298:789-791.
Coyle, Joseph T., “Alzheimer's Disease”, 1987 In:Encylopedia of Neuroscience, Adelman (ed) Birthauser, Boston-Basel-Stuttgart, pp. 29-31.
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation”, J. Mol. Biol. 1992 226:889-896.
Jespers et al., “Guiding the Selection of Human Antibodies from Phage display repertoires to a Single Epitope of an Antigen”, 1994 Bio/Technology 12:899-903.
Katzman et al., “Clinical, Pathological and Neurochemical Changes in Dementia:A Subgroup with Preserved Mental Status and Numerous Neocortical Plaques”, Annals of Neurology 1988 23(2):138-144.
Low et al., “Mimicking Somatic Hypermutation:Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain”, J. Mol. Biol. 1996 260:359-369.
Poljak, Roberto J., “Production and structure of diabodies”, Structure 1994 2:1121-1123.
Wilock et al., “Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice”, J. Neuroscience 2006 26(20):5340-5346.
Zhu et al., “High Level Secretion of a Humanized Bispecific Diabody fromEscherichia coli”, Biotechnology 1996 14:192-196.
Breitling and Dübel 1999 In:Recombinant Antibodies, John Wiley & Sons, Inc., NY p. 115.
Figini et al., “In Vitro Assembly of Repertoires of Antibody Chains on the Surface of of Phage by Renaturation”, J. Mol. Biol. 1994 239:68-78.
Holliger et al., “Diabodies”:Small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA 1993 90:64444-6448.
An Zhiqiang
Kinney Gene
Strohl William R.
Emch Gregory S
Kolker Daniel E.
Licata & Tyrrell P.C.
Merck & Co. , Inc.
LandOfFree
Anti-ADDL monoclonal antibody and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-ADDL monoclonal antibody and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-ADDL monoclonal antibody and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4226356